ACE-031
Also known as: ACVR2B-Fc
ACE-031 (ramatercept) is a soluble fusion protein of the activin receptor IIB (ActRIIB) extracellular domain and human IgG1 Fc, developed by Acceleron Pharma as a myostatin/activin ligand trap for muscle-wasting disorders. Clinical development was HALTED in 2011 after unexpected vascular adverse events (epistaxis, telangiectasia) attributed to off-target BMP-9/10 inhibition. NOT FDA-approved; all further development was terminated. Now sold only as a grey-market research chemical. WADA-prohibited (myostatin inhibitor).
Who's worth your money for ACE-031
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (89) of 2 scored sellers
$159 · 1mg
Best value
Lowest $/mg among scored sellers
$32.00 · 1mg
Average price
$120.83/mg
Sellers
8
45-day trend
+19.7%
6 of 8 sellers have a current price· 1 stale hidden· 3 unverified hidden
Top Merit pick
🇺🇸 Peptidology89✓ verified at source · 23h ago
$159.00/mg +31.6% vs avg$159
1mg
no purity- 🇭🇰 zztai Peptide Ltd43
✓ verified at source · 23h ago
$32.00/mg -73.5% vs avg$32.00
1mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch ACE-031
Get one email when the market actually moves — no newsletter, no noise.
About ACE-031
CAS
1621169-52-5
Molecular formula
C133H227N43O33
Typical dose range
0.02–3 mg/kg subcutaneous (single or every 2–4 weeks; based on Phase 1/2 clinical trials)
Half-life
~10–15 days (human pharmacokinetic data from Phase 1 trial)
COAs for ACE-031
3 third-party tests across 1 vendor. Each card links to the full report.
For
ACE-031
by Kimera Chems· batch KC-ACE-GRN1
For
ACE-031
by Ruo Bio
Purity not on file
For
ACE-031
by Ruo Bio
16 citations indexed for ACE-031
Study · 2026
ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus)
Pharmacological blockade of ligands for the activin receptor type IIB (ActRIIB) e.g., myostatin and activin A is associated with improvements in murine skeletal muscle mass and function.
animal · 2026
Fibro-Adipogenic Progenitors Regulate Orofacial Neuromuscular Junction Regeneration via Myostatin
Background Orofacial and limb muscles differ in embryonic origin and regenerative capacity. Neuromuscular junction (NMJ) regeneration is critical for muscle restoration both histologically and functionally. The relative potential of orofacial and limb muscles to form postsynaptic apparatuses remains elusive.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
review · 2026
Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025
Alongside the considerable advances and accomplishments in drug research and development, the breadth of anti-doping research topics has also continued to grow.
review · 2026
Myostatin Research: From Molecular Understanding to Clinical Translation for Musculoskeletal and Metabolic Disorders
Myostatin (Mstn), a well-characterized member of the transforming growth factor-β (TGF-β) superfamily, serves as a key negative regulator of skeletal muscle mass. Its overactivation is closely associated with the pathogenesis of various musculoskeletal and metabolic disorders.
Study · 2025
Gel Electrophoretic Detection of Black Market ACE-031
The usage of ACE-031 (Ramatercept), a dimeric fusion protein consisting of a human activin receptor IIB (ACVR2B) fragment linked to an Fc-part of human IgG1, is banned according to chapter S4.3 of the "WADA 2024 List of Prohibited Substances and Methods" due to its potential performance enhancing properties.